Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s ...
Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the ...
A key skin protein may control immune overreactions, explaining painful rare conditions and pointing to new treatment paths ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to ...
This is a serious, toxin-mediated skin infection caused by the Staphylococcus aureus bacteria, primarily affecting children ...
Hosted on MSN
16 Weird Diseases You Won’t Believe Are Real
Zombies are the stuff of science fiction, right? Well, people who suffer from Cotard’s syndrome are convinced they are dead or, at the very least, their internal organs are failing. They may refuse to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results